Evidence map›Paper›PMID 36429974›Full record

ArticleInternational journal of environmental research and public health2022

Eight Months of Serological Follow-Up of Anti-SARS-CoV-2 Antibodies in France: A Study among an Adult Population.

Dorine Decarreaux, Julie Sevila, Shirley Masse, Lisandru Capai, Toscane Fourié, Paola Mariela Saba Villarroel, Abdennour Amroun, Elif Nurtop, Matthieu Vareille, Thierry Blanchon and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Dorine DecarreauxLaboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France.
Julie SevilaLaboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France.ORCID 0000-0001-9507-996X
Shirley MasseLaboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France.ORCID 0000-0002-3659-4512
Lisandru CapaiLaboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France.ORCID 0000-0002-3618-1582
Toscane FouriéUnité des Virus émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France.ORCID 0000-0001-7806-4205
Paola Mariela Saba VillarroelUnité des Virus émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France.ORCID 0000-0002-8695-5283
Abdennour AmrounUnité des Virus émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France.ORCID 0000-0001-6052-3944
Elif NurtopUnité des Virus émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France.ORCID 0000-0002-9715-8394
Matthieu VareilleLaboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France.
Thierry BlanchonINSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, 75012 Paris, France.
Xavier de LamballerieUnité des Virus émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France.
Remi CharrelUnité des Virus émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France.ORCID 0000-0002-7675-8251
Alessandra FalchiLaboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France.ORCID 0000-0003-0799-1460
Inserm · FRUniversité de Corse Pascal Paoli · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUncertainties remain regarding the nature and durability of the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).

aimThis study investigated immunoglobulin G response and neutralizing activity to evaluate the mean antibody concentrations and response duration induced by each vaccination regimen in a French adult population.

methodsA study including blood sampling and questionnaires was carried out from November 2020 to July 2021 with three separate follow-up phases. Spike proteins and neutralizing antibodies were quantified using ELISA and a virus-neutralization test.

resultsOverall, 295 participants were included. Seroprevalences were 11.5% (n = 34), 10.5% (n = 31), and 68.1% (n = 201) in phases 1, 2, and 3, respectively. Importantly, 5.8% (n = 17) of participants lost their natural antibodies. Antibody response of participants with only a prior infection was 88.2 BAU/mL, significantly lower than those vaccinated, which was 1909.3 BAU/mL (

conclusionThese results demonstrated that single infection does not confer effective protection against SARS-CoV-2.

Indexed as

COVID-19Spike Glycoprotein, CoronavirusAdultAntibodies, ViralFollow-Up StudiesHumansSARS-CoV-2Antibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2antibodiesCOVID-19long-lasting immunityseroconversionvaccination

Identifiers

PMID36429974
PMCPMC9691066
OpenAlexW4309740968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.